Appeals court overturns ruling in Axonics-Medtronic neurostim patent dispute

The court said the patent board’s “refusal to consider the new arguments and evidence was erroneous.” 

By Nick Paul Taylor • Aug. 8, 2023

J&J subsidiary gains approval for heart ablation devices to use without fluoroscopy

The expanded label could limit exposure to radiation while patients are treated for heart arrhythmias.

By Elise Reuter • Aug. 7, 2023

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

Medtronic expected to prevail at FDA renal denervation vote despite data doubts: analysts

Needham analysts predict the experts will vote in favor of Medtronic and put the device on track to target a $1 billion-plus market.

By Nick Paul Taylor • Aug. 7, 2023

Anne-Françoise Nesmes to step down as Smith+Nephew CFO next year

The announcement comes as Smith+Nephew raised its forecast for the year to a 6% to 7% revenue increase, due to more favorable market conditions. 

By Nick Paul Taylor • Aug. 7, 2023

Stryker raises earnings forecast as procedures return to pre-pandemic levels

The company expects elevated procedure demand to continue into 2024 due to surgery backlogs.

By Elise Reuter • Aug. 4, 2023

Q&A: How Monogram’s CEO plans to disrupt robotic joint replacement surgery

The robot developer’s CEO, Benjamin Sexson, tells MedTech Dive why he believes the orthopedics market needs a fresh approach to joint reconstruction.

By Susan Kelly • Aug. 4, 2023

Penumbra says stroke device delayed at least 12 months due to FDA request

The setback stalls “a meaningful new product catalyst,” but the growth of Penumbra’s other devices could cushion the impact, analysts said.

By Nick Paul Taylor • Aug. 4, 2023

Outset pauses shipments of dialysis accessory after FDA warning letter, denting sales outlook

The halt prompted the company to predict it will now hit the bottom end of its full-year revenue range, a revision that surprised some analysts.

By Nick Paul Taylor • Aug. 4, 2023

BD prepares for relaunch of Alaris pump, raises revenue forecast

The pump relaunch isn’t expected to contribute much to this year’s revenue, but could help Becton Dickinson reach its long-term financial goals. 

By Elise Reuter • Aug. 3, 2023

CMS inpatient final rule will have muted impact on medtech companies, analysts say

The CMS disclosed add-on payments that will continue in 2024 and named products that received approval under the breakthrough devices pathway.

By Nick Paul Taylor • Aug. 3, 2023

Baxter recalls infusion pumps over risk of false alarms

Baxter made a software fix last year after it found pumps weren't issuing an occlusion alarm. Now, the devices might issue alarms even when there isn't a blockage.

By Elise Reuter • Aug. 2, 2023

Cooper scraps $875M takeover of Cook Medical business after FTC investigation

The FTC said ending the planned acquisition “ensures that critical reproductive health markets remain competitive.” 

By Nick Paul Taylor • Aug. 2, 2023

Varian logistics slow growth at Siemens Healthineers in Q3

Healthineers has worked through some logistics problems but now faces a race to install Varian equipment at customer sites. 

By Nick Paul Taylor • Aug. 2, 2023

Terumo receives FDA clearance for automated whole blood processing system

The device automates additional steps needed to separate platelets from the rest of the blood, giving blood centers more capacity.

By Elise Reuter • Aug. 1, 2023

Abbott pulls Trifecta heart valves from US market over deterioration rate

The action removes a rival to Edwards Lifesciences and Medtronic for the surgical aortic valve replacement market.

By Nick Paul Taylor • Aug. 1, 2023

Vicarious expects to perform first human procedure with robot next year

The company, after disclosing layoffs in February, said it has gained clarity on its regulatory pathway following pre-submission meetings with the FDA.

By Susan Kelly • July 31, 2023

Integra warns impact of plant closure will continue into 2024, with delays possible

Management has built a buffer into the plan but cautioned unforeseen events could cause its timeline to slip.

By Nick Paul Taylor • July 31, 2023

GE HealthCare oxygen sensor recall gets Class I label from FDA

GE warned that the sensors can limit the effectiveness of cardiac defibrillation, expose patients to electrical currents, or give inaccurate blood oxygen readings. 

By Nick Paul Taylor • July 31, 2023

Thermo Fisher eyes $450M in cost cuts due to slowing demand

The pullback in spending will include layoffs and lower investments in some areas of the business, company executives said.

By Susan Kelly • July 28, 2023

FDA shares draft guidance on studying medtech treatments for opioid use disorder

The FDA aims to address challenges including inaccurate self-reported drug use, missing data and the need to show the durability of the treatment.

By Nick Paul Taylor • July 28, 2023

Dexcom hails CGM share gains as driver of 25% revenue growth in Q2

International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.

By Nick Paul Taylor • July 28, 2023

Abbott recall of heart catheter categorized as Class I event

Abbott plans to win approval for a modified steerable product and bring it to market as a replacement for the recalled device.

By Nick Paul Taylor • July 27, 2023

Boston Scientific raises full-year forecast again, fueled by strong Q2

The company boosted its outlook for the second consecutive quarter and said patients face waitlists for procedures using its devices.

By Susan Kelly • July 27, 2023

Edwards’ TAVR results hurt by pandemic aftereffects and competition in Q2

Staffing is still not where Edwards “would have projected to be in absence of the pandemic.”

By Nick Paul Taylor • July 27, 2023

Teleflex to expand urology portfolio with $600M acquisition

The company reached an agreement to buy Palette Life Sciences, as it looks to grow through acquisitions.

By Elise Reuter • July 26, 2023